Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis

Abstract

Objective: The relationship between multiple sclerosis (MS) and Sjögren syndrome (SS) is controversial. Nine patients, previously diagnosed with primary progressive MS (PPMS) and who fulfilled the diagnostic criteria for SS, are described. Methods: The European classification criteria for SS were used to study nine PPMS patients that complained of sicca complex symptoms. The following tests were performed: Schirmer test, rose bengal staining, salivary scintigraphy, minor salivary gland biopsy and serologic tests (antibodies Ro/SS-A, La/SS-B and antinuclear antibodies). Results: The nine patients met criteria to be diagnosed with SS (at least four criteria). A ll patients were women with a mean age of 46.6 years at symptom onset. Spastic paraparesis was the presenting symptom in all patients, and spinal cord magnetic resonance imaging (MRI) showed abnormalities in most; anti-Ro and anti-La antibodies were mostly negative. Conclusions: Some MS patients, predominantly women over 45 years of age, with progressive spastic paraparesis, antiextractable nuclear antigen antibodies (Ro/SS-A or La/SS-B) negative and with abnormalities in spinal cord MRI, may have SS as an additional or alternative diagnosis.

Keywords

antibodies Ro/La autoimmune diseases magnetic resonance imaging myelopathy primary progressive multiple sclerosis Sjögren syndrome

Get full access to this article

View all access options for this article.

References

Jacobsson LTH , Axell TE , Hansen BU , Henricsson VJ et al. Dry eyes or mouth and epidemiological study in Swedish adults, with special reference to primary Sjögren’s syndrome . J Autoimmunity 1989; 2: 521-527 .

Kruize AA , Hené RJ , van der Heide A , Bodeutsch C et al. Long-term follow-up of patients with Sjö gren’s syndrome . Arthritis Rheum 1996; 39: 297-303 .

Alexander GE , Provost TT , Stevens MB , Alexander EL. Sjö gren’s syndrome: central nervous system manifestations . Neurology 1981; 31: 1391-1396 .

Alexander EL , Malinow K , Lejewski JE , Jerdan MS et al. Primary Sjögren’s syndrome with central nervous system disease mimicking multiple sclerosis . Ann Intern Med 1986; 104: 323-330 .

Noseworthy JH , Bass BH , Vandervoort MK , Ebers GC , Rice GP et al. The prevalence of primary Sjögren’s syndrome in a multiple sclerosis population . Ann Neurol 1989; 25: 95-98 .

Miró J , Pena-Sagredo JL , Berciano J , Insua S et al. Prevalence of primary Sjö gren’s syndrome in patients with multiple sclerosis . Ann Neurol 1990; 27: 582-584 .

Vitali C , Bombardieri S , Moutsopoulos HM , Coll J et al. Assessment of the European classification criteria for Sjö gren’s syndrome in a series of clinically defined cases: results of a prospective multicentre study . Ann Rheum Dis 1996; 55: 116-121 .

Moore PM , Lisak RP.

Multiple sclerosis and Sjögren’s syndrome: a problem in diagnosis or in definition of two disorders of unknown etiology?

Ann Neurol 1990; 27: 585-586 .

Marzo ME , Tintoré M , Molina C , Comabella M. Multiple sclerosis and Sjögren syndrome . Eur J Neurol 1996; 3(Suppl 4): 20-20 .

10.

Thompson AJ , Montalban X , Barkhof F , Brochet B et al. Diagnostic criteria for primary progressive multiple sclerosis. A position paper . Ann Neurol 2000; 47: 831-835 .

11.

Stevenson VL , Miller DH , Rovaris M , Barkhof F et al. Primary and transitional progressive MS. A clinical and MRI cross-sectional study . Neurology 1999; 52: 839-845 .

12.

Tintoré M , Rovira A , Brieva L , Grive E et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS . Mult Scler 2001; 7: 359-363 .

13.

Kurtzke J. Rating neurologic impairment in multiple sclerosis . Neurology 1983; 33: 1444-1452 .

14.

Rovira A , Tintoré M , Brieva L , Aymerich X et al. Brain and cervical MR imaging and clinical cross-sectional study in primary progressive multiple sclerosis . Mult Scler 2001; 7(Suppl 1): S45-S45 .

15.

Brieva L , Pericot I , Rovira A , Galan I. Validation of primary progressive multiple sclerosis criteria in a sample of patients included in a phase II placebo controlled trial . Rev Neurol (Paris) 2000; 156(Suppl 3): S35-S35 .

16.

Vitali C , Bombardieri S , Jonsson R , Moutsopoulous HM et al. classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group . Ann Rheum Dis 2002; 61: 554-558 .

17.

De Seze J , Devos D , Castelnovo G , Labauge P et al. The prevalence of Sjö gren’s syndrome in patients with primary progressive multiple sclerosis . Neurology 2001; 57: 1359-1363 .

18.

Poser CM. Diseases of the myelin sheath. In: Bajer AB , Baker LH eds. Clinical neurology, volume 2. Philadelphia, PA: JB Lippincott Company , 1983.

19.

Alexander EL , Ranzenbach MR , Kumar AJ , Kozachuk WE et al. Anti-Ro (SS-A) auto-antibodies in central nervous system disease associated with Sjö gren’s syndrome (CNS-SS). Clinical, neuroimaging, and angiographic correlates . Neurology 1994; 44: 899-908 .

20.

Alexander EL , Beall SS , Gordon B , Selnes OA et al. Magnetic resonance imaging of cerebral lesions in patients with Sjö g-ren’s syndrome . Ann Intern Med 1988; 108: 815-823 .

21.

De Seze J , Stojkovic T , Hachulla E , Breteau G et al. Myélopathies et syndrome de Gougerot-Sjögren: étude clinique, radiologique et profil évolutif . Rev Neurol (Paris) 2001; 157: 669-678 .

22.

Williams CS , Butler E , Roman GC. Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide . Arch Neurol 2001; 58: 815-819 .

23.

Hawley RJ , Hendricks WT. Treatment of Sjögren syndrome myelopathy with azathioprine and steroids . Arch Neurol 2002; 59: 875-875 .